Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Multiple Sclerosis News

MS Society Marks One Year Anniversary Of EndMS Campaign, Canada

Main Category: Multiple Sclerosis
Article Date: 17 Sep 2009 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:2 stars

2 (4 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

With over $41 million raised, five regional research and training centres launched and a growing number of educational events aimed at MS researchers and trainees, the Multiple Sclerosis Society of Canada proudly marked one year since the launch of its endMS capital campaign.

"The achievements since the inception of our campaign are significant and were made possible thanks to generosity of donors who have helped us reach more than two thirds of our financial goal to date," says Yves Savoie, president and chief executive officer of the MS Society. "The endMS campaign has brought us clarity of vision and a point of focus for all MS stakeholders. While this is only the beginning and much work remains, we are confident that the efforts of the past year will aid in our quest to end this disease."

The goal of endMS is to raise $60 million to fund research activities and establish the endMS Research and Training Network. In doing so, the MS Society aims to fund the best research, accelerate discovery in the field of MS and find a cure in the shortest possible timeframe.

Accomplishments of the past year include:

- the establishment of five regional research and training centres involving over 100 researchers and over 250 trainees
- $41.3 million raised from a variety of donors from coast-to-coast
- educational events like the endMS Summer School that brought together established MS researchers and a new generation of trainees interested in the field of MS

"I am extremely pleased with the progress that has been made in our first year of activity," says Dr. Jack Antel, scientific director of the endMS Research and Training Network and neurology professor at McGill University. "We have drawn fresh talent into the field of MS, created new learning opportunities and built an infrastructure that fosters collaboration. I think it is safe to say that year one of the endMS Research and Training Network has been a great success."

To learn more, volunteer or donate to the MS Society of Canada visit http://www.endMS.ca or http://www.mssociety.ca.

Source
MS Society of Canada




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Hydrangea Root Shows Promise In Treating Autoimmune Disorders
05 Jun 2009
US researchers found that a drug made from the root of the hydrangea plant, which has for centuries been used in Chinese medicine, showed promising results in treating autoimmune disorders such as rheumatoid arthritis...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

An MS Drug Back on the Market image An MS Drug Back on the Market

After being suspended from the market for safety reasons, natalizumab is again available for the treatment of multiple sclerosis. Safeguards are in place because of a small risk in developing a serious brain infection. Should you consider taking this drug...

View more videos...